Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...
Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al.· Cancer Research· 0 citations
Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...
Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al.· Cancer Research· 0 citations
The findings demonstrate the effectiveness of CA19-9 CAR T cells in GI cancers using various pre-clinical tumor models, providing a rationale for further clinical development.
Fei-Yan Mo, Austin L. Good, Jayne C. McDevitt et al.· Gastroenterology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.